Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23022IDB-L5

Select Item

Empower your strategies with our Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024 report and make more profitable business decisions.

Respiratory syncytial virus (RSV) infection is a respiratory disease. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache, and fever. Treatment includes proper medication and hygiene practice.

The Respiratory Syncytial Virus (RSV) Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Respiratory Syncytial Virus (RSV) Infections
Key Targets
· Respiratory Syncytial Virus Fusion Protein; Respiratory Syncytial Virus RNA Directed RNA Polymerase L; Toll Like Receptor 4; RNA Directed RNA Polymerase; Solute Carrier Family 22 Member 8; Respiratory Syncytial Virus Attachment Glycoprotein; Pulmonary Surfactant Associated Protein D; Human SARS Coronavirus 2 RNA Dependent RNA Polymerase; Glucocorticoid Receptor; and Interferon Alpha/Beta Receptor 1
Key Mechanisms of Action
· Respiratory Syncytial Virus Fusion Protein Inhibitor; Respiratory Syncytial Virus RNA Directed RNA Polymerase L Inhibitor; Respiratory Syncytial Virus Attachment Glycoprotein Inhibitor; RNA Directed RNA Polymerase Inhibitor; Pulmonary Surfactant Associated Protein D Replacement; Solute Carrier Family 22 Member 8 Inhibitor; Human SARS Coronavirus 2 RNA Dependent RNA Polymerase Inhibitor; Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha Agonist; Fatty Acid Synthase Inhibitor; and Glucocorticoid Receptor Agonist
Key Routes of Administration
· Intramuscular; Oral; Nasal; Intravenous; Inhalational; Parenteral; Intrapulmonary; Sublingual; and Intratracheal
Key Molecule Types
· Small Molecule; Subunit Vaccine; Monoclonal Antibody; mRNA Vaccine; Vaccine; Live Attenuated Vaccine; Recombinant Vector Vaccine; Recombinant Protein; Peptide; and Protein
Major Companies
· Sanofi; The National Institute of Allergy and Infectious Diseases; Pfizer Inc; Moderna Inc; GSK plc; AstraZeneca Plc; Enanta Pharmaceuticals Inc; Shanghai Ark Biopharmaceutical Co Ltd; TechnoVax Inc; and Vicebio Ltd

Scope

  • Therapeutics in Development: Covering 185 molecules, with 160 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Respiratory Syncytial Virus (RSV) Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Respiratory Syncytial Virus (RSV) Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Respiratory Syncytial Virus (RSV) Infections treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

60 Degrees Pharmaceuticals Inc
Abhelix LLC
Abivax SA
ADMA Biologics Inc
Advac LLC
Advagene Biopharma Co Ltd
AIM Vaccine Co Ltd
Airway Therapeutics Inc
AlloVir Inc
Amniotics AB
Anima Biotech Inc
Aposense Ltd
Aridis Pharmaceuticals Inc
Artificial Cell Technologies Inc
Ascletis Pharma Inc
Asterivir SA
AstraZeneca Plc
Atea Pharmaceuticals Inc
Atriva Therapeutics GmbH
Auro Vaccines LLC
AVM Biotechnology LLC
Baiya Phytopharm Co Ltd
Beijing Advaccine Biotechnology Company Ltd
Beijing Health Guard Biotechnology Inc
Beijing Tricision Biotherapeutics Inc
Bill & Melinda Gates Medical Research Institute
BioComo Inc
Biological E Ltd
Bioxytran Inc
Blue Lake Biotechnology Inc
BravoVax Co Ltd
Calder Biosciences Inc
Celestial Therapeutics Inc
Centre for Drug Design and Discovery
Changchun Bcht Biotechnology Co Ltd
Chengdu Aoda Biotechnology Co Ltd
Chengdu WestGene Biopharma Co Ltd
Chongqing Zhifei Biological Products Co Ltd
Cidara Therapeutics Inc
Clover Biopharmaceuticals Ltd
Codagenix Inc
ConserV Bioscience Ltd
Curevac NV
Daiichi Sankyo Co Ltd
Decoy Therapeutics Inc
Enanta Pharmaceuticals Inc
Enyo Pharma SA
Esperovax Inc
Eucure (Beijing) Biopharma Co Ltd
Exopharm Ltd
F. Hoffmann-La Roche Ltd
Foundation For Neglected Disease Research
Georgia State University
Ghent University
Gilead Sciences Inc
GSK plc
HanaVax Inc
Heartland Vaccines LLC
HES-SO Valais-Wallis
iBio Inc
Icosavax Inc
IDBiologics Inc
ILiAD Biotechnologies LLC
Immorna Hangzhou Biotechnology Co Ltd
Imophoron Ltd
IMV Inc
Inhalon Biopharma Inc
Inovio Pharmaceuticals Inc
Inventprise LLC
InvisiShield Technologies Ltd
iX Biopharma Ltd
Johnson & Johnson
KARE Biosciences Inc
Kidswell Bio Corp
King Saud University
Mabxience Holding SL
Mapp Biopharmaceutical Inc
McMaster University
Meissa Vaccines Inc
Merck & Co Inc
MicroQuin Ltd
Moderna Inc
NanoViricides Inc
National Taiwan University
NeuClone Pty Ltd
Neuracle Science Co Ltd
NextCell Pharma AB
Novavax Inc
Oita University Institute of Advanced Medicine Inc
Pfizer Inc
Pinetree Therapeutics Inc
Pneumagen Ltd
Poolbeg Pharma Plc
Posvax Co Ltd
Prime Vector Technologies GmbH
Primmune Therapeutics Inc
Prosetta Biosciences Inc
Prosit Sole Biotechnology (Beijing) Co Ltd
ReAlta Life Sciences Inc
Red Queen Therapeutics Inc
RedHill Biopharma Ltd
Research Institute of Influenza
Riboscience LLC
RNAimmune Inc
Ruiyang (Suzhou) Biotechnology Co Ltd
Sagimet Biosciences Inc
Sanofi
Sciogen LLC
Sciwind Biosciences Co Ltd
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Ark Biopharmaceutical Co Ltd
Shionogi & Co Ltd
Signia Therapeutics
SK Bioscience Ltd
Stemirna Therapeutics Ltd
Suzhou Abogen Biosciences Co Ltd
Suzhou Vigonvita Life Sciences Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
TechnoVax Inc
The Chinese University of Hong Kong
The National Institute of Allergy and Infectious Diseases
The University of Manchester
Trimunocor Ltd
TrippBio Inc
UMass Chan Medical School
University of Georgia
University of Pittsburgh
University of Queensland
Uvax Bio LLC
Vanderbilt University
Vault Pharma Inc
Vaxart Inc
Vaxxel SAS
Vernagen Inc
Vicebio Ltd
Vir Biotechnology Inc
Viramatix Sdn Bhd
Viravaxx AG
Virometix AG
VLP Biotech Inc
Walvax Biotechnology Co Ltd
X4 Pharmaceuticals Inc
XBiotech Inc
Zhengzhou University
Zhuhai Trinomab Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Respiratory Syncytial Virus (RSV) Infections reports
Pharmaceuticals
New
Pharma M&A Deals H1 2026 - Top Themes: Strategic Intelligence
$495 | July 2026
Pharmaceuticals
New
Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment,…
$17,995 | July 2026
Pharmaceuticals
New
Melanoma: Epidemiology Forecast to 2035
$9,995 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024 in real time.

  • Access a live Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more